Katalin Susztak, MD, PhD
PHILADELPHIA – Roughly one million people die of untreated kidney failure, worldwide, each year. Despite the major personal and economic burden, only a few new approaches have been deployed to treat or cure kidney disease over the last 40 years. Metabolic changes related to an enzyme “helper molecule” — called nicotinamide adenine dinucleotide (NAD) — may serve as the basis for a future treatment or preventive measure for kidney disease, according to a discovery by a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania. This work was published this month in Nature Metabolism.
Metabolic changes related to NAD may offer a new therapeutic target to improve the course of kidney disease. By mapping metabolite changes in healthy and diseased mouse and human kidneys, the Penn scientists consistently identified differences in levels between healthy and diseased kidneys, including a prominent decrease in NAD in those that were diseased. But when mice in the study were provided with an over-the-counter supplement, it was shown to be effective in reversing NAD loss. This indicates that NAD could play an important role in protecting from kidney dysfunction.
“We hope that this research can lead to improved care in the future. So when patients have metabolite changes, they can receive treatment before kidney disorders arise,” said co-lead investigator Katalin Susztak, MD, PhD, a professor of Nephrology and member of the Institute for Diabetes, Obesity, and Metabolism (IDOM) and Kidney Innovation Center at Penn Medicine.
Joseph Baur, PhD
Susztak and her colleagues — including co-lead investigator Joseph Baur, PhD, a professor of Physiology at Penn and member of the IDOM and first author Tomohito Doke, MD, PhD, a postdoctoral fellow in Susztak’s lab — are working to fill a gap in research. Prior to this study, samples from human patients have not been used in metabolomic studies, meaning the studies of small molecules (like metabolites), in relation to kidney disease.
Using unbiased metabolomic studies, the team identified changes in NAD metabolism in both mouse and human kidneys. In the mouse studies, they showed that using a common supplement, nicotinamide riboside or nicotinamide mononucleotide, to boost NAD protected mice from kidney dysfunction by protecting the mitochondria — the powerhouses — of kidney tubule cells.
Kidney tubule cells are used to return critical filtered nutrients to the body’s blood stream. And when the mitochondria in those cells are damaged, the researchers found, a pathway causing inflammation and kidney disease development is activated. By preventing the damage to mitochondria, NAD supplements suppressed this inflammation and protected mice from kidney injury.
“Identifying these downstream mechanisms that are sensitive to NAD is critical to understanding which conditions may benefit from NAD supplementation,” said Baur.
With these findings, the study team hopes that their research will serve as a springboard for further studies into the role of metabolite changes in kidney dysfunction, as well as the development of new pharmaceuticals to prevent and treat kidney disease.
This research was supported by the National Institutes of Health (R01DK087653, R01DK076077, and R01DK105821). Datasets produced in this study are available at Susztak Lab Kidney Biobank.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $9.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 47,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.